Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

NorthStar closes $100M in financing to expand domestic Mo-99 production

The company received $75 million at closing from funds managed by Oberland Capital Management. NorthStar has the option to draw another $25 million before December 31, 2020.

Thumbnail

PET/CT radiotracer benefits clinicians, prostate cancer patients

18F-DCFPyL PSMA PET/CT imaging accurately localized biochemically recurrent prostate cancer and prompted clinicians to change their management plans in more than 80% of patients, according to a recent study in the Journal of Nuclear Medicine.

Thumbnail

DOE land transfer puts company on-track for domestic Mo-99 facility

The U.S. Department of Energy (DOE) recently transferred land in Oak Ridge, Tennessee, to Coquí Radio Pharmaceuticals, pushing the company closer to establishing a domestic production of Molybdenum-99 (Mo-99), an isotope used in many molecular imaging exams.

Thumbnail

PET brain scans help connect the dots between CTE, tackle football

PET brain scans of living former NFL players with cognitive and neuropsychiatric symptoms showed higher tau levels than controls in brain regions typically affected by chronic traumatic encephalopathy (CTE), according to an April 11 study published in the New England Journal of Medicine (NEJM).

Thumbnail

68Ga-PSMA-11 PET has positive impact on prostate cancer patients

The PET radiotracer 68Ga-PSMA-11 improved the detection of biochemically recurrent prostate cancer, according to results of a prospective trial published in JAMA Oncology.

Thumbnail

ACR, SNMMI create new clinical registry for nuclear medicine

The American College of Radiology (ACR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are collaborating to create a new clinical data registry to support high-quality practice and care in nuclear medicine.

Thumbnail

JAMA: Amyloid PET changed clinical management in 60% of patients with dementia

Amyloid PET imaging greatly influenced the clinical management of patients with mild cognitive impairment (MCI) and dementia, according to the first phase of a multicenter trial published April 2 in JAMA.

Thumbnail

New radiotracers may gain ground in FDG territory

PET/CT with the radiotracer 18F-FDG may have met its match at cancer detection in two new “FAPI” tracers based on gallium-68. The acronym stands for fibroblast activation protein inhibitor, and in a recent trial the new tracers equaled or bettered FDG PET/CT on image quality, required no fasting and yielded images in less time than FDG PET/CT.